DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ariel Cohen - 1 Rich Liu - 1 Amy Butte - 1 Cohen - 1 Cohen wouldn't - 1 he's - 1
Top related locs:
Navan U.S
Top related orgs:
Navan - 1 CNBC - 1 Navan Travel - 1 New York Stock Exchange - 1

Search resuls for: "Cohen wouldn't"


2 mentions found


☆ $9 billion travel tech firm Navan on track to hit profitability this year and 'not far' from IPO, CEO says
  + stars: | 2024-05-20 | by ( Ryan Browne | ) www.cnbc.com   time to read: +2 min
Asked about when Navan would choose to go public, the firm's CEO and co-founder Ariel Cohen said the company is close to reaching that milestone. "We can see the signals," he said, adding that Navan has been adjusting its leadership structure and making changes to its board in a signal of maturity. Last month saw Navan announce the return of Rich Liu, formerly Navan's chief revenue officer and "an expert on scaling companies from seed to IPO and beyond," to the business as CEO of Navan Travel, the company's travel division. While Cohen wouldn't commit to a date for Navan's eventual IPO, he said the business was "not far" from being ready for a stock market listing. The company is on track to become cash-flow positive and achieve profitability for the first time this year, he said.
Persons: Ariel Cohen, Rich Liu, Amy Butte, Cohen, Cohen wouldn't, he's Organizations: Navan, CNBC, Navan Travel, New York Stock Exchange Locations: Navan, U.S
☆ A controversial ALS drug potentially worth $1 billion is on the cusp of FDA approval. It could change Amylyx's fortunes and be a much-needed treatment for the rare disease.
  + stars: | 2022-09-26 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +7 min
The FDA may soon approve a new treatment for ALS, also known as Lou Gehrig's disease. If approved, Amylyx Pharmaceuticals's drug, AMX0035, will be a new treatment option for patients. A new drug for amyotrophic lateral sclerosis, more commonly known as ALS or Lou Gehrig's disease, is on the cusp of approval from the US Food and Drug Administration. The association said that treatment has the support of the larger ALS community and urged the FDA to "swiftly approve" AMX0035. By comparison, there are around 30,000 ALS patients in the US, meaning reimbursing AMX0035 would pose a much lighter burden on the CMS.
0 next >>
Total: 2